Posted in | News | Nanobusiness

TriQuint's New $16.2M DARPA Contract Will Pursue Radically-Enhanced Gallium Nitride Circuits for Defense, Aerospace

TriQuint Semiconductor (NASDAQ:TQNT), a leading RF products manufacturer and foundry services provider, today announced that it has been awarded a $16.2 million Defense Advanced Research Projects Agency (DARPA) multi-year Gallium Nitride (GaN) R+D contract to create complex, high dynamic range circuits for future defense and aerospace applications.

TriQuint received its DARPA contract to advance GaN research and develop new generations of compound semiconductor circuits through the Nitride Electrical NeXt-Generation Technology (NEXT) program. TriQuint's Principal Investigator, Senior Fellow Dr. Paul Saunier, explained that achieving NEXT program goals could lead to GaN circuits as radically different as today’s computers are compared to those in the 1980s.

“GaN is already recognized for its ability to handle more power per square millimeter than other semiconductor technologies like gallium arsenide, and much more so than silicon. Yet even with the advances TriQuint has pioneered, today’s analog GaN technology has frequency and power limits.

“NEXT circuits will be ‘game-changing’ technology that could radically improve performance in defense and aerospace applications like phased array radar and communications. NEXT calls for complex digital GaN circuits that also have very high breakdown voltages—something that silicon can’t do, and that is also beyond the scope of today’s other semiconductor processes,” said Dr. Saunier.

Dr. David Fanning, TriQuint’s Program Manager for NEXT, described the different segments of the new DARPA contract and key performance milestones. “The initial phase will run two years, pursuing devices that can operate at 300 GHz with essential yield levels of a small circuit. The 18-month Phase II program will push the operating frequency to 400 GHz while increasing yield and circuit size. The third and final 12-month segment will seek to extend the operating frequency to 500 GHz while also substantially increasing yield and circuit size,” he said.

Dr. Fanning explained that another key aspect of the NEXT program will be to develop enhancement-depletion (E/D) mode GaN circuits, similar to the E/D circuits that TriQuint uses for greater functionality and power handling in its Gallium Arsenide devices.

The TriQuint NEXT team will include IQE plc, a leading manufacturer of advanced GaN semiconductor wafers. TriQuint will also team with University of Notre Dame Professors Patrick Fay, Debdeep Jena, Greg Snider and Huili Xing to explore alternative wafer materials and circuit designs. University of Illinois Professor Ilesanmi Adesida will assist with work to develop advanced fabrication processes.

TriQuint has been a leader in GaN research for both defense and civilian applications since 1999. In addition to defense products, TriQuint has released GaN amplifiers for civilian applications and has provided commercial GaN foundry services since 2008. TriQuint was selected in 2009 by DARPA to lead a Phase III effort of the Wide Bandgap Semiconductor (WGBS-RF) R&D program that is developing high-power, wideband GaN circuits with defense and aerospace applications.

TriQuint is a leading manufacturer of high-performance, high-reliability GaN and GaAs integrated circuits as well as surface acoustic and bulk acoustic wave (SAW / BAW) filters for communications and radar programs. TriQuint’s standard products portfolio and R&D leadership have made the company a leading supplier to Boeing Company, Lockheed Martin Corporation, Northrop Grumman, Raytheon and other major defense contractors. TriQuint also serves consumer markets such as mobile phones, wireless LAN and GPS.

For more information about TriQuint products for defense and aerospace, visit www.triquint.com. Register for product updates and our newsletter at: www.triquint.com/rf.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.